Tempest Therapeutics, Inc. - Common Stock TPST 深 滬
已收盤 12-24 16:00:00 美东时间
3.08
+0.040
+1.32%
華盛通- 最 高3.10
- 今 開3.08
- 成交量 6.17万股
- 最 低 3.01
- 昨 收 3.04
- 總市值 1084.25万
- 52周最高 13.65
- 市盈率 靜 --
- 換手率 1.75%
- 52周最低 2.87
- 委 比 -80.48%
- 總股本 352.03万
- 歷史最高 3381.30
- 量 比 0.76
- 振 幅 2.96%
- 歷史最低 2.21
- 每 手 1
- 風險率 2.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tempest Therapeutics Announces ~$4.25M Offering Of 1.2M Common Stock, 1.2M Warrants At $3.625/Share
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a
11-25 21:03
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.
11-20 00:33
Tempest Therapeutics Signs Agreements To Acquire Certain Dual-Targeting Chimeric Antigen Receptor-T Programs From Factor Bioscience
Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "the Company"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced that it has
11-19 22:04
Tempest Therapeutics Q3 EPS $(0.79) Beats $(3.27) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(3.27) by 75.84 percent. This is a 85.15 percent increase over losses of $(5.32) per share
11-05 21:34
国元证券-电子行业周报：英伟达投资50亿美元入股英特尔，三星HBM3e通过英伟达验证-250922
（来源：研报虎） 报告要点： 本周(2025.9.15-2025.9.19)市场回顾 1)海外AI芯片指数本周下跌0.80%，本周成分股表现差异较大，M...
09-22 15:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Tempest Therapeutics Q2 EPS $(2.07) Beats $(3.23) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of $(3.23) by 35.91 percent. This is a 62.5 percent increase over losses of $(5.52) per share
08-12 04:22
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Received clearance to proceed with pivotal trial of amezalpat combination thera...
08-12 04:12
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
<p>Tempest Therapeutics received NMPA approval to initiate a pivotal trial for amezalpat in combination with atezolizumab and bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) in China. This approval builds on prior FDA and EMA clearances for the Phase 3 study, which aims to evaluate the efficacy of amezalpat against the current standard of care. HCC is a leading cause of cancer death globally, ...
06-30 12:00
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
Tempest Therapeutics entered into a definitive agreement with a single institutional investor for a registered direct offering of 739,000 shares of its common stock at $6.25 per share, yielding approximately $4.6 million in gross proceeds. The funds will primarily support its strategic alternative process and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The offering is under a shelf registration statem...
06-11 12:00
